Avanos Medical (AVNS) Net Cash Flow (2013 - 2026)

Avanos Medical (AVNS) has 14 years of Net Cash Flow data on file, last reported at -$23.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 85.6% year-over-year to -$23.2 million; the trailing twelve-month figure through Mar 2026 stood at -$33.6 million (down 250.67% YoY), and the FY2025 full-year result was -$22.9 million, down 195.02% from the prior year.
• Net Cash Flow slipped to -$23.2 million in Q1 2026, from $18.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $26.9 million in Q3 2023 to a low of -$32.9 million in Q1 2023.
• A 5-year average of -$2.9 million and a median of -$9.6 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow jumped 1787.5% in 2022 and tumbled 404.35% in 2023, its largest moves.
• Tracing AVNS's Net Cash Flow over 5 years: stood at $6.9 million in 2022, then plunged by 404.35% to -$21.0 million in 2023, then soared by 209.05% to $22.9 million in 2024, then slipped by 18.34% to $18.7 million in 2025, then tumbled by 224.06% to -$23.2 million in 2026.
• Business Quant data shows AVNS's Net Cash Flow at -$23.2 million in Q1 2026, $18.7 million in Q4 2025, and -$19.5 million in Q3 2025.